Again stretching to find interesting connections
in the genomics programs...
Celera Genomics announced three year gene discovery
agreement with Rhone-Poulenc Rorer. to identify
therapeutic targets for a variety of human diseases,
including asthma, cancer, and cardiovascular disorders,
by applying Celera's proprietary GeneTag(tm) technology
to RPR's disease model systems.
biz.yahoo.com
Celera's GeneTag process, a global gene expression profiling technology, provides a rapid, quantitative measurement of all
RNA transcripts present in a cell or tissue. It is a highly
sensitive technique capable of detecting rare and novel
transcripts in quantities less than one copy per cell.
Aventis: Rhone-Poulenc Shareholders Vote by More Than 97%
For the Planned Merger with Hoechst
biz.yahoo.com
But...it would probably be some months before anyone can
see where Aventis genomics versus Hoechst Ariad genomics
will be in relation to one another.
The Hoechst-Ariad genomics center agreement continues
to March 2002...and HOE/RP will have been merged into
Aventis for more than two years by that time.
From the Ariad annual report:
'The technologies currently established in
the Genomics Center include custom cDNA-based
gene chip arrays (Molecular Dynamics), commercial
high-density chip arrays (Affymetrix), cDNA library
construction, high-throughput EST sequencing, high-
throughput FL cloning and sequencing, integrated
automation systems, genetic sreen methodologies for
gene discovery, mouse gene targeting technologies,
and bioinformatics tools for analysis of DNA
sequencing and gene chip data.'
A letter to shareholders went out in August of last
year...will be looking forward to this year's letter.
If I don't see one, then maybe I will have to ask
for some help from the thread in designing a letter
to ship off to Laurie Allen--who is the Senior VP,
Corporate Development. |
